CRANBURY, N.J., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced updated results from a Phase I clinical study of its first-in-class cancer metabolism targeted therapeutic, CPI-613, for the treatment of advanced hematological malignancies. The results were presented by the principal investigator, Timothy S. Pardee, MD, of the Comprehensive Cancer Center of Wake Forest Baptist Medical Center, during an oral presentation on Monday, December 9, 2013, at the 2013 American Society of Hematology (ASH) Annual Meeting and Exposition, in New Orleans, LA.
Help employers find you! Check out all the jobs and post your resume.
